TherapeuticsMD (TXMD) Price to Earnings (2011 - 2026)

TherapeuticsMD (TXMD) has reported Price to Earnings for 16 consecutive years, with 165.02 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Price to Earnings rose 577.26% year-over-year to 165.02; the trailing twelve-month figure through Jun 2026 stood at 138.26 (down 203.8% YoY), and the FY2025 full-year result was 33.16, down 629.14% from the prior year.
• Price to Earnings retreated to 165.02 in Q2 2026 per TXMD's latest filing, from 246.1 in the prior quarter.
• Across five years, Price to Earnings topped out at 246.1 in Q1 2026 and bottomed at 35.98 in Q1 2024.
• Historically, Price to Earnings has averaged 18.87 across 5 years, with a median of 6.41 in 2022.
• The sharpest annual moves came in 2023 and 2026: Price to Earnings sank 4200.76% in 2023, then soared 1601.06% in 2026.
• Over 5 years, Price to Earnings stood at 0.68 in 2022, then tumbled by 4200.76% to 28.02 in 2023, then jumped by 185.08% to 23.84 in 2024, then sank by 234.81% to 32.14 in 2025, then surged by 613.47% to 165.02 in 2026.
• According to Business Quant data, Price to Earnings over the past three periods registered 165.02, 246.1, and 32.14 for Q2 2026, Q1 2026, and Q4 2025 respectively.